Moderna (NASDAQ:MRNA) projected 2025 sales at the upper end of its forecast as a smaller-than-expected decline in U.S. vaccination rates and aggressive cost-cutting help the biotech giant navigate the post-pandemic landscape.
The Cambridge, Massachusetts-based company expects to report approximately $1.9 billion in revenue for the year, according to a statement Monday.
While that figure remains a fraction of the $18.4 billion generated during the 2022 pandemic peak, it lands near the top of its previously guided range of $1.6 billion to $2 billion.
Chief Financial Officer James Mock said in an interview that U.S. retail vaccination rates fell about 26% in 2025.
While a significant drop, it was less severe than the 40% decline the company had braced for, providing a floor for revenue.
The drugmaker is also tightening its belt, slashing $200 million from its operating-expense forecast to a new range of $5 billion to $5.2 billion.
The results provide a measure of stability for a company that has seen its stock struggle as demand for Covid-19 shots cratered.
Moderna is now pivoting toward a broader respiratory franchise and experimental "second act" therapies in oncology and rare diseases.